“T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer” (2016), by Eric Tran et al. Immunology and Microbiology research paper. Original abstract below, unchanged. No free PDF was found.

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

Eric Tran, Paul F. Robbins, Yong‐Chen Lu et al. · December 7, 2016 · Immunology and Microbiology

Abstract

HLA-C*08:02-restricted tumor-infiltrating lymphocytes that were composed of four different T-cell clonotypes that specifically targeted KRAS G12D. However, one of these lesions had progressed on evaluation 9 months after therapy. The lesion was resected and found to have lost the chromosome 6 haplotype encoding the HLA-C*08:02 class I major histocompatibility complex (MHC) molecule. The loss of expression of this molecule provided a direct mechanism of tumor immune evasion. Thus, the infusion of CD8+ cells targeting mutant KRAS mediated effective antitumor immunotherapy against a cancer that expressed mutant KRAS G12D and HLA-C*08:02.

Source page DOI: 10.1056/nejmoa1609279